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Abstract
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating
ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient
experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings.
Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological
recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity,
as there is significant clinical overlap between these 2 syndromes. Practitioners must remain vigilant of this potential lifethreatening complication in this vulnerable population.
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Introduction
Methylene blue is a phenothiazine derivative that is used in a
variety of roles in clinical practice that range from a dye used in
diagnostic applications to a therapeutic utilized for the treatment of methemoglobinemia. An off-label but common use of
methylene blue in the oncology population is for the treatment
of ifosfamide neurotoxicity.1 Approximately, 10% to 40% of
patients treated with ifosfamide develop encephalopathy.2
Although most cases are self-limited and do not require treatment, the condition can be severe or even fatal.3 Methylene
blue is thought to help in cases of ifosfamide neurotoxicity due
to its inhibition of monoamine oxidase (MAO). This enzyme is
responsible for producing chloroacetaldehyde, the neurotoxic
metabolite of ifosfamide.4 Similar to other MAO inhibitors, a
well-known potential toxicity of methylene blue is serotonin
syndrome, particularly with concomitant use of other serotonergic drugs.5 Based on this risk, the US Food and Drug
Administration has issued a black box warning for the concomitant use of methylene blue with such agents. Serotonin

syndrome is a potentially life-threatening condition. Early recognition and discontinuation of offending agents is essential in
its management. We present a unique case of severe serotonin
syndrome in a patient receiving methylene blue for the treatment of ifosfamide neurotoxicity. This case highlights the diagnostic challenge of identifying serotonin syndrome in a patient
with preexisting encephalopathy. Serotonin syndrome should
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be suspected in patients with worsening mental status after
methylene blue treatment for ifosfamide neurotoxicity, particularly if autonomic dysfunction is present.

Case Report
A 58-year-old woman with a history of hypertension, generalized anxiety disorder, depression, and hepatitis C was diagnosed with retroperitoneal leiomyosarcoma. She underwent
radical resection of the tumor with negative margins and subsequent segmental duodenectomy and inferior vena cava closure. Two years later, she presented with nausea, vomiting, and
right upper quadrant abdominal pain secondary to 2 new retroperitoneal masses. Biopsy confirmed recurrent disease. The
patient was started on chemotherapy with AIM75/10 (doxorubicin 25 mg/m2/d intravenous [IV] over 24 hours on days 1 to
3, ifosfamide 2500 mg/m2/d IV over 24 hours on days 1
through 4, mesna 2500 mg/m2 IV concurrently with ifosfamide
over 24 hours on days 1 through 4, then 2500 mg/m2 IV over
12 hours on day 5).6 The first cycle of Mesna, Adriamycin, and
Ifosfamide (chemotherapy regimen) was complicated by neutropenic fever. The second cycle was also complicated by neutropenic fever, despite a reduction in ifosfamide dose to 2000
mg/m2/d for 4 days. During the third cycle, the patient developed acute altered mental status shortly after receiving her
second dose of ifosfamide despite being on thiamine 100 mg
Oral /peroral (PO) daily as prophylaxis. Other concurrent
scheduled medications at the time included bisacodyl 5 mg
PO daily and docusate-senna 50 to 8.6 mg PO daily for constipation; clonidine 0.2 mg PO twice daily, losartan 50 mg PO
daily, and nifedipine extended release (ER) 60 mg PO every
morning and 90 mg every evening for hypertension; ondansetron 8 mg IV every 8 hours, dexamethasone 18 mg PO daily,
and metoclopramide 10 mg PO at meals and at bedtime for
chemotherapy-induced nausea and vomiting; oxycodone ER
15 mg PO twice daily for pain; fluconazole 200 mg PO daily
for thrush; and paroxetine 20 mg PO daily for generalized
anxiety disorder and depression. She displayed confusion,
memory impairment, and an inability to follow commands or
form coherent speech. Her total delirium observation score was
10. The thiamine dose was increased to 100 mg IV every 4
hours for presumed ifosfamide neurotoxicity. After 2 doses of
IV thiamine and continued neurological decline, methylene
blue 50 mg IV was added every 6 hours. As a precaution, the
patient’s paroxetine, which she had been taking daily for at
least the past 3 years, was discontinued. Over the next 6 to
12 hours and after 2 additional doses of methylene blue, her
status deteriorated further. In addition to worsening confusion
(total delirium observation score of 13), she developed severe
sinus tachycardia (185-210 beats/min), hypertension (increase
from 120/77 to 150/87 mm Hg), diaphoresis, fever (peak temperature 38 C), and combativeness. On physical examination,
she demonstrated hyperreflexia, ocular clonus, spontaneous
muscular clonus, and facial tremors. These symptoms and
physical examination findings led to concern for serotonin syndrome, and as a result, methylene blue was discontinued. Her
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ondansetron was stopped for the same reason. She received IV
lorazepam, metoprolol, acetaminophen, and hydromorphone
for symptomatic management. During the course of her clinical
decline, she was transferred to the critical care unit to provide
elevated measures of care and intubation for airway protection.
Initial laboratory tests, which included blood cell counts, electrolytes, renal function panel, and liver function tests, were
within normal limits. A workup for sepsis consisting of blood
and urine cultures in addition to chest imaging was unremarkable. Computed tomography and magnetic resonance imaging
of the head revealed no acute vascular events or other abnormalities. Intravenous thiamine was continued in combination
with general supportive care measures, and the patient was
monitored closely. Her mentation slowly improved over the
next 6 days in the critical care unit, and she was extubated.
She demonstrated normal memory and fluent speech without
the presence of any uncontrolled movements. After 15 total
days of hospitalization, including 8 in the critical care unit, she
was discharged from the hospital without residual encephalopathic or neurological symptoms. Subsequently, the patient
was seen for a follow-up appointment in the sarcoma ambulatory care clinic to assess her response to therapy and discuss
further disease management. Given the severe toxicities the
patient had experienced with ifosfamide, it was determined that
it would not be safe to rechallenge with the agent. Alternative
options included further systemic therapy with single-agent
doxorubicin or different agents altogether or surgical management. Given that her disease recurrence continued to be oligometastatic and that more systemic therapy would not be likely
to provide any significant benefit, her oncologist elected to
attempt surgical resection with the goal of leaving the patient
with no evidence of disease. Two months later, the patient
underwent resection of regional recurrence of 2 sites of disease.
At last clinic follow-up prior to publication, imaging displayed
no evidence of disease.

Discussion
Serotonin syndrome is a disorder arising from increased serotonergic activity in the central nervous system that is precipitated by medications, drug–drug interactions, or drug overdose
via accidental or purposeful intentions.7 Patients presenting
with this potentially life-threatening condition classically display the triad of autonomic hyperactivity, neuromuscular
abnormalities, and mental status changes. Autonomic overactivation can present as a variety of symptoms ranging from
hypertension, tachypnea, and tachycardia to diaphoresis and
hyperthermia. Mental status changes often include disorientation, delirium, anxiety, or severe agitation.8,9 Potential neuromuscular abnormalities include akathisia, tremor, myoclonus,
or hyperreflexia, with the latter 2 more commonly displayed in
the lower extremities.9
Initial treatment of the disorder is relatively straightforward,
as discontinuing all offending serotonergic agents and managing associated symptoms are primary steps of care. However,
accurately recognizing the disorder is more complex. Serotonin
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Table 1. Commonly Used Agents in the Oncology Population Associated With Increased Risk of Serotonin Syndrome.a
Indication

Class or Specific Agent

Depression

Selective serotonin reuptake inhibitors,
serotonin–norepinephrine reuptake inhibitors,
tricyclic antidepressants, serotonin modulators,
dopamine–norepinephrine reuptake inhibitors,
monoamine-oxidase inhibitors
Pain management Tramadol, methadone, fentanyl
Migraine
5-hydroxytryptamine-1B/1D receptor agonists
(triptan class)
Nausea
5-hydroxytryptamine-3 antagonists,
metoclopramide
Anxiety
Buspirone
Infection
Linezolid, tedizolid
a
Potential agents in the oncology population associated with the increased risk
of serotonin syndrome.

syndrome is a diagnosis of exclusion after other metabolic,
infectious, ischemic, and toxic etiologies are ruled out. Timely
diagnosis is of utmost importance, as the differential is wide
and includes neuroleptic malignant syndrome, anticholinergic
toxicity, sympathomimetic drug intoxication, meningitis, encephalitis, or withdrawal from sedative-hypnotic agents.10 Physical examination is pivotal to this process, and there are several
tools available to aid practitioners in utilizing the information
gathered. Of these, the Hunter Serotonin Toxicity Criteria
(HSTC), found to be more sensitive and specific than Sternbach criteria, appear to be the most useful.11 To meet the
HSTC, a patient must be on a serotonergic agent in addition
to 1 of the 5 following criteria: ocular clonus plus agitation or
diaphoresis, inducible clonus plus agitation or diaphoresis, tremor and hyperreflexia, spontaneous clonus, and hypertonia and
a temperature above 38 C plus ocular or inducible clonus.10,11
Despite the potential utility of the HSTC, appropriate diagnosis
is often delayed or missed altogether. An essential workup
component involves obtaining an extensive, detailed patient
medication history. Doses, dosing schedules, and formulations
for every medication or substance a patient takes prior to onset
of symptoms should be assessed for serotonergic potential. It is
especially imperative to look for any recent changes to a
patient’s regimen, as serotonin syndrome commonly presents
within 24 hours of initiating a new agent or changing the dose
of a current medication.9
Several pharmaceutical agents commonly used in the management of patients with cancer are serotonergic and therefore
can contribute to the risk of serotonin overdose (Table 1).10
Monoamine oxidase inhibitors, while less common in clinical
practice than some of the other agents listed, can be contributory to serotonin syndrome as they effectively inhibit serotonin
metabolism. Methylene blue falls into this category as an inhibitor of both MAO A and MAO B.12 Compounds that are
strong inhibitors of select cytochrome P450 (CYP450)
enzymes can also increase the risk of serotonin overdose via
drug drug interactions. Several of the listed agents are

CYP2C19, CYP2D6, and CYP3A4 substrates and will have
their serotonergic properties greatly increased with concomitant administration of such an inhibitor.10
Encephalopathy is a well-described potential neurologic
complication of treatment with ifosfamide. Neurotoxicity
typically occurs hours or days after drug administration. Initial management includes supportive care, close monitoring,
and slowing the rate of or discontinuing the ifosfamide infusion. Most patients with mild symptoms do not require additional treatment, and the disorder resolves spontaneously.
Methylene blue has been explored as a treatment of ifosfamide neurotoxicity to shorten the duration of severe symptoms and as a prophylactic measure to stop the disorder from
occurring altogether.12 However, evidence demonstrating
benefit for the practice is sparse and is limited to retrospective
reports with no controlled trials. A literature review by Patel1
found that while the agent appeared to work rapidly in select
cases, in most instances, the efficacy of methylene blue was
not well established. This review also made the astute recognition that the potential of ifosfamide neurotoxicity to spontaneously improve complicates any assessment of true
treatment efficacy.1 Still, these shortcomings are not enough
to deter use of the agent in severe cases. Even if uncertain, the
chance for potential benefit that methylene blue offers in
these instances can outweigh the risks of associated adverse
events, including serotonin syndrome.
Methylene blue is known to cause serotonin syndrome, most
commonly with nononcologic uses.13 However, to our knowledge, only 1 previous case of serotonin syndrome has been
reported in association with methylene blue treatment for ifosfamide neurotoxicity.13 Factors that may contribute to the rarity
of this event include relative uncommonness of the treatment
indication, a lower dose of methylene blue than used for other
indications (eg, this report: 50 mg in a 68-kg patient, approximately 0.74 mg/kg), and challenges in establishing the diagnosis of serotonin syndrome in the face of a preexisting
neurological condition. Our case highlights the difficulty in
diagnosis of serotonin syndrome in patients with ifosfamide
neurotoxicity because of symptom overlap between these 2
conditions, including confusion, disorientation, and movement
disorders such as generalized myoclonus.14 In the case reported
here, a diagnosis of serotonin syndrome was strongly suspected
given the correlation between methylene blue initiation and
worsening of symptoms just 5 to 8 hours later as well as the
new development of autonomic dysregulation and classic physical examination findings. Utilizing the HSTC, our case had a
high probability of serotonin syndrome. The resolution of serotonergic symptoms after discontinuation of the agent validated this diagnosis. Of note, the patient was also on several
additional medications that increase the risk of serotonin syndrome, which is common in the oncology population.
Given the unproven benefit of methylene blue in the treatment of ifosfamide neurotoxicity, potential toxicities of this
medication should carry weight in the treatment decision. For
this reason, in our opinion, methylene blue should only be used
in severe cases. In situations where methylene blue is utilized,
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clinicians must consider the diagnosis of serotonin syndrome in
patients with further encephalopathic decline, particularly if
new autonomic dysfunction is present. Rapid recognition of
serotonin syndrome and discontinuation of the offending agent
or agents are essential to proper management.

Conclusions
Methylene blue is a commonly used agent for the treatment of
severe cases of ifosfamide neurotoxicity. However, the administration of methylene blue can precipitate serotonin syndrome.
This risk is increased if other serotonergic medications are
administered concurrently, which is common in the oncology
population. Practitioners should be vigilant to make an early
diagnosis and remove the offending agents to treat this potentially fatal disorder.
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